Is it really over? La Jolla signs acquisition with Tetraphase after outbidding AcelRx, Melinta
La Jolla has staked a claim as the latest victor in the bidding war for Tetraphase, sealing the deal with $43 million in upfront cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
